This Primer describes the current knowledge surrounding B12 deficiency, and highlights improvements in diagnostic methods as well as shifting concepts about the prevalence, causes and manifestations of B12 deficiency
Consequently, the existing evidence level remains limited, and its clinical efficacy and safety lack robust prospective validation
These naturally occurring compounds communicate directly with cells, helping to optimize your bodys own healing and function at the cellular level
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
Although vancomycin has been linked to hepatic injury in case reports, evidence for its role in causing severe multisystem toxicity remains limited ( Tislelizumab, a PD-1 inhibitor, carries a recognized risk of immune-related hepatitis (irH) ( The patient reported chronic heavy alcohol intake (~200 g/day), which is recognized as a susceptibility factor in RUCAM and was incorporated into the risk-factor domain together with age 55 years (maximum contribution)
Dolma S, Lessnick SL, Hahn WC, Stockwell BR Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells
